Search bioRxiv⌕ Search

Biology subjects

Adewunmi, Y.

Publications and source records attributed to Adewunmi, Y..

2 recordsLinked to original sources

Maternal transfer of mRNA LNP-derived, pathogen-specific, monoclonal IgG to suckling mice

Breast milk provides a rich source of naturally derived maternal antibodies that confer passive immunity to infants, protecting them from a variety of respiratory and enteric infections. For at-risk newborns in low- and middle-income countries, supplementing breast milk with pathogen-specific neutralizing and bactericidal antibodies could offer significant short- and long-term health benefits. In this study, we explored the use of mRNA and lipid nanoparticle (LNP) technology to deliver a Vibrio cholerae-specific monoclonal IgG antibody ("ZAC-3") into the milk of lactating mice. Swiss Webster mice were intravenously administered ZAC-3 IgG mRNA-LNPs, and we monitored serum and breast milk for the presence of V. cholerae-specific human IgG1. A single injection of mRNA-LNPs led to rapid and sustained expression of ZAC-3 IgG in both the blood and breast milk of lactating dams. ZAC-3 IgG1 in these samples recognized whole V. cholerae cells by ELISA and exhibited potent vibriocidal activity in the presence of human complement. Furthermore, ZAC-3 IgG was detected in the sera of suckling pups at levels proportional to those in the mothers, demonstrating successful transfer of functional antibodies to the newborns. In conclusion, our findings highlight the potential of mRNA-based monoclonal antibody platforms in the maternal-newborn context and address key challenges associated with the direct delivery of recombinant antibodies.

immunology↗

Antibody Profiles Elicited by Potent and Subpotent Whole Cell Pertussis Vaccines in Mice

Inactivated, whole cell pertussis (wP) vaccines remain at the frontline in the global fight against the resurgence of whooping cough, especially in low- and middle-income countries. However, the reliance on the intracerebral mouse potency test (ic-MPT or Kendrick assay) as the standard batch release assay is challenging for the production of commercial wP vaccines. The ic-MPT is technically challenging, labor intensive and, arguably, incongruous with modern animal welfare guidelines. Replacing the ic-MPT with a whole cell Bordetella pertussis ELISA, the so-called pertussis serology potency test (PSPT), has shown promise, but has been difficult to implement in practice. In this report, we tested the hypothesis that potent and subpotent wP vaccines have distinct serologic profiles in mice that could be developed as a substitute for the ic-MPT. We first established an accelerated decay (thermal stress) protocol in which wP, in the context of DTwP, was rendered >10-fold less effective than unstressed vaccine when evaluated in a mouse model of B. pertussis lung clearance following intranasal challenge. We then screened immune sera on a limited B. pertussis Tahoma I proteome array and identified >30 antigens whose antibody reactivity profiles increased, decreased or were unchanged as a function of wP potency. Interestingly, virtually all the "indicator" antigens identified are known virulence factors or reactive with human convalescent sera, thereby establishing a potential link between wP potency and pertussis infection and immunity. These results bode well for the development of a limited B. pertussis antigen array as a stability-indicating surrogate potency assay for the ic-MPT.

immunology↗